Kihealth Labs
Kihealth Labs research team reviewing molecular diagnostic data

Built to Detect Disease Earlier

Kihealth Labs was founded to transform how disease is detected, monitored, and prevented — by bringing breakthrough molecular diagnostics from scientific discovery into clinical practice.

Explore the platformMeet our leadership

Our Origin

Kihealth Labs began with a stubborn question: why do we wait for late-stage signals when the underlying biology has been speaking for years? Founded by clinicians, scientists, and operators who refused that compromise, the company was built to translate decades of β-cell research into diagnostics clinicians can actually use.

Molecular visualization of pancreatic β-cell research
  1. Discovery

    A new question about β-cells

    Three decades of pancreatic β-cell research established that the cells fail long before glucose ever moves. Kihealth was founded on the conviction that this molecular failure should be measurable in clinical practice — not only in academic labs.

  2. Translation

    From bench to blood test

    The team translated cell-free DNA, methylation, and proinsulin biology into a single liquid-biopsy framework — one blood sample, multi-analyte readout, clinical-grade workflow.

  3. Platform

    InterceptIQ™ takes shape

    A unified molecular intelligence platform emerges: shared chemistry, shared analytics, and multiple programs across diabetes, oncology, and neurodegeneration.

  4. Today

    Clinical practice

    Kihealth Labs is moving early detection out of research and into routine care — for clinicians, patients, employers, and health systems who refuse to wait for late-stage signals.

From Yale to Kihealth

Our science traces directly to foundational pancreatic β-cell research at Yale University and the broader academic community — translated, protected, and engineered into the InterceptIQ™ platform.

  1. 01 · Scientific origins

    Yale University

    Pioneering Type 1 diabetes research at Yale — including work that contributed to teplizumab, the first FDA-approved therapy shown to delay the onset of Stage 3 T1D.

  2. 02 · Foundational discovery

    β-cell Biology

    Identification of cell-free DNA biomarkers released from dying pancreatic β-cells — a direct molecular signal of active injury, years before metabolic decompensation.

  3. 03 · Engineering the platform

    Molecular Diagnostics

    Translation of the underlying biology into a scalable laboratory platform combining low-input cfDNA chemistry, methylation analysis, and AI-driven interpretation.

  4. 04 · Commercialization

    Kihealth Labs

    Launch of the InterceptIQ™ platform through CLIA-certified infrastructure — clinical-grade diagnostics designed for routine practice, research, and pharma collaboration.

The human body sends signals long before disease becomes visible. Our purpose is to listen, measure, and act — so clinicians and patients can intercept disease earlier than ever before.

Our Mission

Bring clinically actionable molecular diagnostics into routine care to identify disease risk earlier, guide intervention, and improve long-term outcomes for patients living with — or at risk of — metabolic, oncologic, and neurodegenerative disease.

Science-led

Every program is grounded in peer-reviewed pancreatic β-cell biology and validated by rigorous clinical research.

Patient-centered

We design diagnostics that fit into real clinical workflows, so more patients benefit from earlier, clearer answers.

Prevention-focused

Our goal is not to manage late-stage disease — it is to intercept metabolic disease before irreversible damage begins.

Why Kihealth

Conventional diagnostics confirm disease that has already taken hold. Kihealth was built to do something fundamentally different — measure the biology that precedes disease, so clinicians can act while there is still time to change the outcome.

Earlier biological detection

Detect molecular injury years before glucose, imaging, or symptoms reveal disease.

Molecular intelligence

Cell-free DNA, methylation, and proinsulin biology fused into a single multi-analyte readout.

Precision diagnostics

Quantitative, reproducible signals — built for clinical decisions, not academic interpretation.

AI-driven interpretation

A machine-learned analytics layer turns multi-analyte signals into clinician-ready answers.

Prevention-focused care

Reframes diagnostics from disease confirmation to disease interception and risk modification.

Scalable platform

One liquid-biopsy workflow extends across diabetes, oncology, and neurodegeneration programs.

The Disease Intercept Platform

InterceptIQ™ is a precision diagnostics platform — not a single test. A shared scientific foundation, a shared liquid-biopsy workflow, and a shared analytics engine power a growing portfolio of disease-focused programs.

Explore InterceptIQ™
BetaIntercept™
Active program

Detects active autoimmune β-cell injury and metabolic dysfunction associated with Type 1 and Type 2 diabetes — years before glucose change.

Future metabolic applications
In development

Therapeutic monitoring for GLP-1 and emerging metabolic therapies, plus extended profiling across the metabolic continuum.

Platform scalability
Architecture

Shared chemistry, shared analytics — OncoIntercept™ and NeuroIntercept™ programs extend the same workflow into oncology and neurodegeneration.

Clinical utility
Practice-ready

Clinical-grade workflow built for routine care: one blood draw, validated assays, and clinician-ready reporting through CLIA infrastructure.

Vision for the Future

We see a future where disease is intercepted, not just managed — where every clinical decision is informed by the molecular biology that precedes symptoms, and where precision medicine reaches every patient who could benefit from it.

Kihealth Labs is committed to advancing early detection, precision diagnostics, and preventive healthcare across metabolic, oncologic, and neurodegenerative disease. We are building the molecular intelligence layer the next generation of medicine will be built on.

A team built for this work

A scientific and operational team spanning endocrinology, molecular biology, regulatory strategy, and healthcare commercialization — guided by a world-class Scientific Advisory Board and Board of Directors.

Meet our leadership

Partner, publish, or join us.

Whether you're a clinician, researcher, health system, or investor — there are several ways to engage with the Kihealth Labs platform.

CareersPartnershipsContact